Key result
Large-scale GWAS maps over 2000 BP signals and 24 resistant hypertension loci.
Why the study?
Hypertension genetics is transitioning from discovery into clinical applications through genome-wide association studies of blood pressure and resistant hypertension, available polygenic risk scores, and regulatory approval of a novel class of antihypertensive treatment. This review highlights recent discoveries and their clinical implications.
Genetic discoveries in hypertension highlight kidney tubular biology and the aldosterone axis, supporting novel therapies like aldosterone synthase inhibitors and clinical evaluation of the mineralocorticoid axis in resistant hypertension.
Answers are grounded in this paper and cite their sources.
Supports targeted aldosterone-axis therapies; leaves open whether polygenic scores or new agents alter hypertension outcomes.
PURPOSE OF REVIEW: Hypertension genetics is transitioning from discovery into clinical applications: there are numerous genome-wide association studies (GWAS) of blood pressure (BP) and more recently resistant hypertension, polygenic risk scores are available, and there is regulatory approval of a novel class of antihypertensive treatment. This review highlights recent discoveries and clinical implications. RECENT FINDINGS: A GWAS of greater than 1 million individuals identified 2103 independent BP signals, explaining more than 60% of common-variant heritability; many candidate genes are expressed in kidney tubular epithelia and adrenal zona glomerulosa. A GWAS (>23 000 cases) of resistant hypertension identified 24 loci with candidate genes mapping to the aldosterone-potassium axis, providing genetics support for selective aldosterone synthase inhibitors and overlap with BP loci. Clinical trials using aldosterone synthase inhibitors, and angiotensinogen-silencing RNA therapies are in Phase 2-3 trials; aprocitentan received regulatory approval for resistant hypertension in 2024. SUMMARY: The genetic architecture of hypertension spans Mendelian disease genes to thousands of common variants, with kidney tubular biology and the aldosterone axis as central biological themes. Multigene panels, primary aldosteronism screening, and mineralocorticoid axis evaluation before accepting apparent resistance are ready for clinical implementation. Polygenic risk scores show promise for trial enrichment and pharmacogenomic stratification, but are not yet ready for individual clinical decisions.
No takes yet. Share an insight, caveat, or question.
Danielli et al. (2026) conducted a review in Hypertension and resistant hypertension. Genome-wide association studies (>1 million individuals) identified 2103 independent blood pressure signals and 24 resistant hypertension loci (>23,000 cases).
Synapse has enriched 10 related papers. Consider them for comparative context: